PMID- 37153893
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20230509
IS  - 1792-1015 (Electronic)
IS  - 1792-0981 (Print)
IS  - 1792-0981 (Linking)
VI  - 25
IP  - 6
DP  - 2023 Jun
TI  - Downregulation of microRNA‑494 inhibits cell proliferation in lung squamous cell 
      carcinoma via the induction of PUMA‑alpha‑mediated apoptosis.
PG  - 242
LID - 10.3892/etm.2023.11941 [doi]
LID - 242
AB  - Increased evidence has shown that abnormal microRNA (miRNA) plays pivotal roles 
      in numerous types of cancer. However, their expression, function and mechanism in 
      lung squamous cell carcinoma (LSCC) remains to be fully elucidated. The aim of 
      the present study was to investigate the suppressive role of miR-494 in LSCC 
      progression and elucidate its regulatory mechanism. By analyzing expression 
      profiles of miRNAs in LSCC tissues using miRNA microarray, it was revealed that 
      miR-494 was significantly upregulated in 22 pairs of LSCC tissues. Subsequently, 
      reverse transcription-quantitative PCR was performed to determine the expression 
      of miR-494 and p53-upregulated-modulator-of-apoptosis-alpha (PUMA-alpha). Western blot 
      analysis was conducted to examine protein levels. Dual-luciferase reporter assay 
      was used to confirm the binding between miR-494 and PUMA-alpha. Annexin 
      V-fluoresceine isothiocyanate/propidium iodide staining and CCK-8 assays were 
      employed to determine cell apoptosis and cell viability, respectively. It was 
      also revealed that miR-494 was highly expressed in LSCC cell lines compared with 
      that in 16HBE cells. Further experiments confirmed that knockdown of miR-494 
      reduced cell viability and induced LSCC apoptosis. Bioinformatics analysis 
      predicted that miR-494 could potentially target PUMA-alpha; also known as 
      Bcl-2-binding component 3, a pro-apoptotic factor, and an inverse correlation 
      between the expression of miR-494 and PUMA-alpha mRNA levels in LSCC tissues was 
      found. Furthermore, PUMA-alpha inhibition could reverse the promoting effect of 
      miR-494 knockdown on apoptosis in LSCC cells. Taken together, these findings 
      demonstrated that miR-494 functions as an oncogene by targeting PUMA-alpha in LSCC, 
      and miR-494 may serve as a novel therapeutic target for treating LSCC.
CI  - Copyright: (c) Gao et al.
FAU - Gao, Xinyuan
AU  - Gao X
AD  - Department of Respiratory and Critical Care, The First Affiliated Hospital of 
      Xinxiang Medical College, Xinxiang, Henan 453100, P.R. China.
FAU - Yang, Xiaohua
AU  - Yang X
AD  - Department of Respiratory and Critical Care, The First Affiliated Hospital of 
      Xinxiang Medical College, Xinxiang, Henan 453100, P.R. China.
FAU - He, Fengzhen
AU  - He F
AD  - Department of Respiratory and Critical Care, The First Affiliated Hospital of 
      Xinxiang Medical College, Xinxiang, Henan 453100, P.R. China.
FAU - Liu, Xue
AU  - Liu X
AD  - Department of Respiratory and Critical Care, The First Affiliated Hospital of 
      Xinxiang Medical College, Xinxiang, Henan 453100, P.R. China.
FAU - Liu, Ding
AU  - Liu D
AD  - Department of Oncology, The First Affiliated Hospital of Xinxiang Medical 
      University, Weihui, Henan 453100, P.R. China.
FAU - Yuan, Xiaomei
AU  - Yuan X
AD  - Department of Respiratory and Critical Care, The First Affiliated Hospital of 
      Xinxiang Medical College, Xinxiang, Henan 453100, P.R. China.
LA  - eng
PT  - Journal Article
DEP - 20230411
PL  - Greece
TA  - Exp Ther Med
JT  - Experimental and therapeutic medicine
JID - 101531947
PMC - PMC10160919
OTO - NOTNLM
OT  - apoptosis
OT  - lung squamous cell carcinoma
OT  - microRNA-494
OT  - p53 upregulated modulator of apoptosis-alpha
OT  - proliferation
COIS- The authors declare that they have no competing interests.
EDAT- 2023/05/08 06:41
MHDA- 2023/05/08 06:42
PMCR- 2023/04/11
CRDT- 2023/05/08 04:22
PHST- 2022/08/07 00:00 [received]
PHST- 2023/01/16 00:00 [accepted]
PHST- 2023/05/08 06:42 [medline]
PHST- 2023/05/08 06:41 [pubmed]
PHST- 2023/05/08 04:22 [entrez]
PHST- 2023/04/11 00:00 [pmc-release]
AID - ETM-25-6-11941 [pii]
AID - 10.3892/etm.2023.11941 [doi]
PST - epublish
SO  - Exp Ther Med. 2023 Apr 11;25(6):242. doi: 10.3892/etm.2023.11941. eCollection 
      2023 Jun.